MedRhythms, Inc.
7
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.3%
1 terminated/withdrawn out of 7 trials
83.3%
-3.2% vs industry average
0%
0 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Outcomes and Health Economics of Stroke Using Rhythmic Auditory Stimulation
Role: lead
Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
Role: lead
Pilot Randomized Controlled Study of the Impact of MedRhythms' MR-010 in Acute Stroke
Role: collaborator
Facilitators and Barriers to the Clinical Implementation of MR-001
Role: lead
Feasibility and Preliminary Effects of MR-005 in Persons With Parkinson Disease
Role: lead
Post-Stroke Walking Speed and Community Ambulation Conversion Study
Role: lead
Rhythmic Auditory Stimulation & Gait Training
Role: collaborator
All 7 trials loaded